Indeed, several studies have shown that targeting Mcl-1 by either chemical agents or genetic approaches resulted in a significant enhanced anti-cancer activity of ABT-737 in both in vitro and in vivo models [9,25,26]. This evidence concerns the gene MCL1 and cancer.